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2004Objective: The aim of the present study was to evaluate the very-long-term results of the Carpentier-Edwards
pericardial bioprosthesis in the mitral position.
Methods: From 1984 to 2011, 450 Carpentier-Edwards PERIMOUNT pericardial mitral bioprostheses were
implanted in 404 consecutive patients (mean age, 68 years; 53% female). Patients undergoing multiple valve
replacements were excluded. The clinical, operative, and follow-up data were prospectively recorded. The
mean follow-up was 7.2  5.1 years, for a total of 3258 valve-years. The follow-up data were 97.8% complete.
Results: The operative mortality rate was 3.3%. A total of 188 late deaths occurred, for a linearized rate of
5.8%/valve-year. At 20 years, the overall actuarial survival rate was 16.9%  3.9%. Age at implantation, pre-
operative New York Heart Association class III or IV, and redo procedure were significant risk factors affecting
late survival. The actuarial freedom from complications at 20 years was thromboembolism, 83.9%  7.6%;
hemorrhage, 80.2%  10.8%; endocarditis, 94.8%  1.4%; structural valve deterioration, 23.7%  6.9%;
and explantation owing to structural valve deterioration, 40.5%  8.0%. The competing risk analysis demon-
strated an actual risk of explantation owing to structural valve deterioration at 20 years of 25.5%  2.9%. The
expected valve durability was 16.6 years for the entire cohort (11.4, 16.6, and 19.4 years for patients aged<60,
60 to 70, and>70 years, respectively).
Conclusions:With a low rate of valve-related events at 20 years and, in particular, a low rate of structural valve
deterioration, the Carpentier-Edwards PERIMOUNT pericardial bioprosthesis remains a reliable choice for a
mitral tissue valve, especially in patients>60 years old. (J Thorac Cardiovasc Surg 2014;148:2004-11)Supplemental material is available online.
The Carpentier-Edwards PERIMOUNT bioprosthesis (Ed-
wardsLifesciences, Irvine,Calif) is a trileaflet valve consisting
of bovine pericardial leaflets mounted underneath a flexible
cobalt-chromium stent. This valve was designed to minimize
structural valve deterioration (SVD), which had plagued
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The Journal of Thoracic and Cardiovascular Surhemodynamic superiority conferred by pericardial valve
construction relative to porcine valves. The middle-term
results were promising, with a low rate of valve-related events
and, especially, a low rate of deterioration.3,4
The present study reports our 25-year experience with the
Carpentier-Edwards pericardial valve implanted in the
mitral position starting in 1984.METHODS
From August 1984 to March 2011, 450 Carpentier-Edwards PERI-
MOUNT pericardial bioprostheses were implanted in 404 consecutive
patients for mitral valve replacement (MVR) in our hospital. Of the
404 patients, 46 required a second bioprosthesis and were considered as
new patients with a new valve. The indications for MVR with a
bioprosthesis rather than a mechanical valve were patients aged 60 years
and those who were younger if they had met specific conditions (eg, endo-
carditis, short anticipated life expectancy because of comorbidities,
contraindication to oral anticoagulant treatment, informed patient choice).
During the study period, 240 mechanical mitral valve replacements and
700 mitral valve repairs were performed; therefore, the present series
concerned one third of the patients who had undergone mitral valve surgery
in our department. Patients undergoing multiple valve replacement were
excluded from the present study; however, no patients were excluded
because of other concomitant operations. The preoperative characteristics
of the cohort are listed in Table 1.
The data from all patients undergoing valve replacement at our institu-
tion since 1984 were prospectively entered into a computer database, andgery c November 2014
Abbreviations and Acronyms
AUC ¼ area under the curve
CI ¼ confidence interval
HR ¼ hazard ratio
MST ¼ median survival time
MVR ¼ mitral valve replacement
SVD ¼ structural valve deterioration
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questionnaires were mailed to all the patients. If the questionnaires were
not returned or the patient reported an adverse event, telephone or personal
interviews were conducted. All patients underwent transthoracic
echocardiography at the follow-up examination. For the patients who
died, the Social Security Death Index was used to confirm the date.
Themean follow-upperiodwas7.2 5.1years (range, 0 to24.8) for a total
of 3258 valve-years. The follow-up datawere complete for 97.8% of the pop-
ulation. The closing interval for the present study was 12 months. Morbidity
and mortality were defined according to the guidelines of The Society of
Thoracic Surgeons and the American Association for Thoracic Surgery.5,6
The operative techniques used were similar to those previously
reported.7 The patients underwent surgery through a median sternotomy
with standard cardiopulmonary bypass and moderate hypothermia (32C-
36C). Myocardial protection was accomplished using crystalloid or blood
cardioplegia and topical cooling. The surgical techniques remained
constant throughout the entire experience. The bioprosthesis was rinsed
in saline solution and secured with simple interrupted sutures. Beginning
in 1988, the subvalvular apparatus of the posterior and anterior leaflets
was preserved whenever possible. The operative data are listed in Table 1.
The postoperative anticoagulant protocol changed during the study
period. Before 1998, it included heparin for 2 days, followed by 1 month
of calcium heparin (activated clotting time, 1.5 normal) or acenocoumarol
(international normalized ratio, 1.5-2.0; Ciba-Geigy, Rueil-Malmaison,
France). After 1 month, the anticoagulation treatment was discontinued.
Since 1998, the practice of postoperative anticoagulation for patients
with a bioprosthesis has been discontinued, with the exception of those
in atrial fibrillation (target international normalized ratio, 2-3). Antiplatelet
agents were prescribed for cardiac (ischemic heart disease) or vascular
(ischemic vascular accident, occlusive arterial disease of the lower limbs)
indications only.
Because the present study involved only a retrospective medical record
review and used only de-identified data, it qualified for exemption from
institutional review board approval.
Statistical Analysis
Early events (30 days after surgery) were calculated as simple percent-
ages (number of complications divided by number of patients). Linearized
rates for late events (>30 days after surgery) represent the number of com-
plications per 100 valve-years. Kaplan-Meier actuarial analyses, including
both early and late events, are presented, with the Greenwood formula for
the variance. Testing differences between 2 survival curves was done
using the log-rank or Mantel-Haenszel test. Each patient’s life expectancy
was calculated using the demographic life tables published by the French
national demographic study institute (Institut national d’etudes
demographiques).8 Life expectancy was dependent on patient age, year
of surgery, and gender. Life expectancy and expected valve durability
were estimated by the median survival time (MST)—the point at which
the Kaplan-Meier curve crosses 0.5 probability, and with the restricted
mean or area under the Kaplan-Meier curve (area under the curve
[AUC])—truncated with the latest available upper limit. Multivariate
Cox proportional hazards regression analysis was used to identify the
risk factors and estimate the hazard ratios (HRs) of the baseline hazardThe Journal of Thoracic and Carfor mortality and valve deterioration. For nonfatal events, such as structural
valve deterioration (SVD), competing risk analyses,9,10 often referred to as
‘‘actual’’ analyses in published studies, were performed using the R cmprsk
package, version 2.13.1 (The R Project for Statistical Computing).RESULTS
Operative Mortality, Functional Status, and Survival
Rates
A total of 15 deaths were reported in the operative period,
for a total operative mortality rate of 3.3%.
The postoperative New York Heart Association func-
tional class was available for all patients who were reported
as alive with the valve in place at the last follow-up point
(n ¼ 156). Of these patients, 72% showed significant
improvement from the preoperative score.
A total of 188 late deaths were recorded, for a linearized
rate of 5.8%/valve-year. Of these, 40 (1.2%/valve-year)
were designated as valve-related: thromboembolism in 5,
hemorrhage in 4, endocarditis in 4, SVD in 4, and sudden
death in 23.
At 20 years, the overall actuarial survival rate was 16.9%
 3.9%, and the valve-related actuarial survival rate was
62.4%  9.0% (Figure 1). Patient age at implantation
(HR, 1.06; P< .001), New York Heart Association class
III-IV (HR, 1.86; P < .001), and reoperation for SVD
(HR, 1.51; P ¼ .021) were significant risk factors affecting
late survival.
All main events and early event rates, linearized rates,
Kaplan-Meier estimates at 10, 15 and 20 years, and
2 freedom from event expectancy estimates (MST and
AUC) are listed in Table 2.Valve-Related Complications
Thromboembolic events. No case of valve thrombosis
was reported.
A total of 23 thromboembolic events were reported, for a
linearized rate of 0.7%/valve-year. Of these, 5 occurred
during the first 30 postoperative days (1.1%); 7 led to death
and 4 to permanent neurologic deficit. Finally, 12 were
considered minor, with the patient having a complete recov-
ery. The 10-, 15-, and 20-year freedom from thromboembo-
lism rate was 93.4%  1.5%, 91.5%  2.4%, and 83.9%
 7.6%, respectively.
Bleeding events. A total of 27 bleeding events were re-
ported (linearized rate, 0.8%/valve-year) and led to death
for 4 patients. Of these, 22 occurred in the postoperative
period, and 16 were related to the anticoagulant use. The
mean age of the patients with bleeding events (66.6 years)
was similar to that of the patients without events (68.1
years). During the follow-up period, 65% of the patients
had used warfarin for anticoagulation, 75% of whom
were reported to have atrial fibrillation or atrial flutter. For
the others, anticoagulant agents were prescribed for cardiac
(congestive heart failure), vascular arterial (ischemicdiovascular Surgery c Volume 148, Number 5 2005
FIGURE 1. Kaplan-Meier estimates of overall and valve-related mortality.
TABLE 1. Patient demographics
Variable Value
Mitral prostheses (n) 450
Patients (n) 404
Age (y)
Range 22-89
Mean  SD 68.0  10.4
Gender
Male 210 (46.7)
Female 240 (53.3)
Etiology
Degenerative 160 (35.6)
Reoperative 127 (28.2)
Rheumatic 117 (26.0)
Ischemic 26 (5.8)
Endocarditis 20 (4.4)
Lesion
Regurgitation 277 (61.6)
Stenosis 109 (24.2)
Mixed 64 (14.2)
Preoperative NYHA
I 56 (12.4)
II 139 (30.9)
III 156 (34.7)
IV 99 (22.0)
Atrial fibrillation 171 (38.0)
Preoperative LVEF (%)
>50 415 (92.2)
35-50 30 (6.8)
20-34 4 (0.8)
<20 1 (0.2)
Valve size (mm)
25 6 (1.3)
27 166 (36.9)
29 187 (41.6)
31 80 (17.8)
33 11 (2.4)
Associated procedures 193 (42.9)
CABG 69 (15.3)
Operative mortality 15 (3.3)
Follow-up (y)
Total, valve-year 3257.8
Mean  SD 7.2  5.1
Range 0-24.8
Lost to follow-up 10 (2.2)
Data presented as n (%) or mean  SD and range. SD, Standard deviation; NYHA,
NewYork Heart Association functional class; LVEF, left ventricular ejection fraction;
CABG, coronary artery bypass grafting.
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limbs), or venous (venous thrombosis, pulmonary embo-
lism) indications. The 20-year actuarial freedom from
anticoagulant-related hemorrhage was 80.2%  10.8%.
Operated valve endocarditis. Endocarditis was reported
in 15 patients. Of these patients, 4 died without reoperation,
4 underwent reoperation, and 7 were successfully treated
using antibiotics alone. The 20-year actuarial freedom
from endocarditis was 94.8%  1.4%.2006 The Journal of Thoracic and Cardiovascular SurNonstructural dysfunction. No clinically significant he-
molysis was recorded in the absence of structural valve
dysfunction.
Structural valve deterioration. The mitral bioprosthesis
was considered to have deteriorated on strict echocardio-
graphic assessment when severe regurgitation (effective re-
gurgitant orifice area  40 mm2) or stenosis (mean
transvalvular gradient> 8 mm Hg) was observed, even if
the patient was asymptomatic. SVD was reported in 76 pa-
tients (2.3%/valve-year). Of these patients, 63 underwent
reoperation, and 13 had died rapidly after SVD had been
diagnosed. SVD had occurred because of excessive calcifi-
cation in most cases (76.3%), followed by leaflet tear
(19.7%), or both (3.9%). The mean interval to the onset
of SVD was significantly longer in the case of leaflet tear
than for calcification (14.8 years; 95% confidence interval
[CI], 12.7-16.9; and 10.1 years; 95% CI, 9.2-11.0, respec-
tively; P<.001).
The actuarial freedom from SVD at 20 years was 23.7%
 6.9%, and the actuarial freedom from explantation
because of SVD at 20 years was 40.5%  8.0%. The ex-
pected valve durability, calculated by the MST from the
actuarial freedom from SVD, was 16.6 years (95% CI,
14.5-19.1). Patient age at implantation, with a HR of 0.96
(95% CI, 0.94-0.97), was the only significant risk factor
affecting SVD. No difference was observed for gender,
valve size, etiology, or New York Heart Association
classification.
To answer patients’ often asked question: ‘‘What is the
chance that a reoperation will be needed because of valve
deterioration after a certain amount of time?’’, competing
risk analysis was performed. Because the intervention has
usually been performed late in the patient’s life, thegery c November 2014
TABLE 2. Summary of main events—freedom from events with Kaplan-Meier estimates
Variable Event rate (30 d) Linearized rate (>30 d)
Kaplan-Meier estimate (%)
MST (y) AUC (y)At 10 y At 15 y At 20 y
Mortality 15 (3.3) 188 (5.8%/vy) 56.1  2.8 35.1  3.5 16.9  3.9 11.8 11.9
Valve-related mortality 15 (3.3) 40 (1.2%/vy) 86.3  2.1 78.1  3.5 62.4  9.0 NA* 20.0
Reoperation 1 (0.2) 81 (2.5%/vy) 81.0  2.7 57.6  4.3 37.1  7.4 16.8 16.6
Any complication 12 (2.7) 133 (4.1%/vy) 63.5  3.1 39.1  4.2 11.4  4.9 12.1 12.6
Operated valve endocarditis 1 (0.2) 14 (0.4%/vy) 94.8  1.4 94.8  1.4 94.8  1.4 NA* 23.8
Thromboembolism 5 (1.1) 18 (0.6%/vy) 93.4  1.5 91.5  2.4 83.9  7.6 NA* 22.8
Bleeding 5 (1.1) 22 (0.7%/vy) 91.6  1.7 91.6  1.7 80.2  10.8 NA* 21.6
SVD 0 (0.0) 76 (2.3%/vy) 83.9  2.7 55.4  4.8 23.7  6.9 16.6 16.1
Explantation for SVD 0 (0.0) 63 (1.9%/vy) 86.3  2.5 62.8  4.5 40.5  8.0 19.0 17.5
Data presented as n (%), unless otherwise noted.MST, Median survival time; AUC, area under the curve; NA, not applicable; SVD, structural valve deterioration. *Survival curve
did not cross 0.5; thus, the MST was not applicable.
FIGURE 2. Kaplan-Meier estimates of explantation because of structural
valve deterioration (SVD) stratified by age group.
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greater than the probability of reoperation for SVD
(Figure E1). The cumulative risk of valve explantation
owing to SVD at 15 and 20 years was 20.4%  2.5%
and 25.5%  2.9%, respectively, much lower than the cor-
responding actuarial estimates (37.2%  4.5% and 59.5%
 8.0%) and also lower than the corresponding probability
of death (57.5%  3.0% and 67.7%  3.2%).
SVD stratified by age group. The population was divided
into different age groups at implantation for analysis of the
actuarial SVD and reoperation because of SVD. For pa-
tients<65 years old, the freedom from SVD at 15 and 20
years was 47.3%  6.5% and 19.1%  7.0%, with 19
and 5 patients at risk, respectively. For patients aged 65
years, the corresponding estimates were 62.5%  7.3%
and 29.6% 14.6%, with 15 and 2 patients at risk, respec-
tively. This difference was statistically significant (P¼ .04).
The valve durability for patients aged<65 years and those
aged 65 years was 14.2 and 18.9 years, respectively.
The freedom from reoperation for SVD at 15 and 20 years
was 49.5%  6.4% and 25.1%  7.5%, respectively, for
the younger group and 76.8%  5.2% at 15 years for the
older group, remaining constant thereafter.
Figure 2 displays the additional age groups for reopera-
tion because of SVD (60, 61-70, and>70 years). The dif-
ference among the groups was highly significant (P¼ .001),
with an expected interval to reoperation for SVD of 11.9
and 19.0 years for patients aged 60 years and 61 to 70
years, respectively. For patients aged 50 to 60 years at im-
plantation, the expected valve durability remained >15
years (15.7 years) and the estimated time to requiring reop-
eration was >16 years (16.2 years). The results of
competing risk regression analysis to evaluate the cumula-
tive risk of reoperation for SVD with age as the unique co-
variate are shown in Figure 3. The corresponding HR was
0.93 (95% CI, 0.91-0.94). The data were also computed
to indicate the number of years a patient could expect before
requiring reoperation for SVD depending on their age at im-
plantation (Table 3).The Journal of Thoracic and CarFinally, we subdivided the cohort by age decile and dis-
played the sample life expectancy and expected valve dura-
bility relative to the life expectancy of the general
population in France.8 Mitral valve disease and surgical
valve replacement appeared to reduce life expectancy
compared with that of the general population; however,
this difference declined significantly as patient age at sur-
gery increased. Except for the first decile of age at implan-
tation (15-56 years), the expected valve durability estimate
was greater than the life expectancy after MVR (Figure E2).
Reoperation. A total of 82 reoperations were reported; 1
during the operative period because of severe aortic regur-
gitation and 81 in the postoperative period (linearized
rate, 2.5%/valve-year). Eight mitral prostheses were ex-
planted prophylactically during another cardiac operation:
6 aortic valve replacements, 1 coronary artery bypass graft-
ing, and 1 tricuspid valve repair. Finally, 73 reoperationsdiovascular Surgery c Volume 148, Number 5 2007
FIGURE 3. Competing risk estimates of explantation because of struc-
tural valve deterioration (SVD) stratified by age group.
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dehiscence, and 4 because of operated valve endocarditis.
The 20-year actuarial freedom from valve explantation for
all causes was 37.1%  7.4%.DISCUSSION
In the present study, we evaluated the long-term dura-
bility of the Carpentier-Edwards PERIMOUNT pericardial
bioprosthesis in the mitral position and report the longest
term follow-up data with this prosthesis, with 8 patients at
risk at 20 years and 1 at 24.8 years. Furthermore, to our
knowledge, ours is the longest study in terms of total
follow-up data, with>3250 valve-years in the mitral posi-
tion. Our report also presents the patient’s viewpoint: de-
pending on patient age at surgery, we have estimated the
risk and number of years before a reoperation would be
required because of SVD.Survival
In accordance with the guidelines, deaths from sudden
or unknown causes were conservatively included in theTABLE 3. Explantation for SVD stratified by age group—competing risk
Probability (%) 50 55 60
5 7.0 7.6 8.1
10 8.1 8.7 9.3
15 9.0 10.0 10.9
20 9.3 10.7 11.9
25 10.3 11.5 14.5
Data presented as interval to reoperation for SVD in years. A 60-year-old patient would h
probability increasing 25% after 14.5 years. SVD, Structural valve deterioration.
2008 The Journal of Thoracic and Cardiovascular Survalve-related category. In our experience, the overall sur-
vival rate was 16.9%  3.9%, and the freedom from
valve-related mortality was 61.7%  8.9% at 20 years.
For the group treated from 1984 to 1991, who had follow-
up data in 2011 for 20 years, the life expectancy of a pa-
tient 70 years old in France was 11.2 to 12.3 years for men
and 14.6 to 15.9 years for women.8 From our analyzed
cohort, 50% of our patients were still alive at 11.8 years,
and the AUC was 11.9 years. Therefore, the life expectancy
after MVR was similar to the age- and gender-adjusted life
expectancy for the general population. The valve-related
life expectancy demonstrated an AUC of 19.8 years,
much greater than the general population life expectancy.
Analyzing the survival rates, it is noteworthy that one third
of MVRs were for degenerative mitral valve disease. To un-
derstand this low repair rate, one should remember that our
series has reported a 25-year experience and began when
mitral valve repair was not yet the reference standard for
degenerative mitral valve surgery.Expected Valve Durability (SVD, Reoperation for
SVD)
In the present study, SVD was determined strictly from
the annual echocardiographic assessment. We reported
76 patients with SVD (2.3%/valve-year), of whom 63 un-
derwent reoperation—all elective—with no operative mor-
tality. The major consideration with a deteriorated
bioprosthesis, as stated by McGiffin and colleagues,11 is
‘‘the competing risks of death without re-replacement and
re-replacement before death.’’ Jamieson and colleagues12
reported a mortality rate of 6.3% for isolated mitral valve
repeat replacement. Only age at implantation and at explan-
tation were significant risk factors for mortality. They
concluded that the mortality rate after reoperation for
SVD could be significantly reduced by optimizing the
timing of surgery before the onset of advanced symptoms
and emergency status.12 Consistent with these data, our
good results concerning reoperations can be explained
because patients with deteriorated mitral bioprostheses un-
derwent reoperation, even if they were asymptomatic. More
recently, Wilbring and colleagues13 reported very prom-
ising results with transapical mitral valve-in-valve(actual) estimates
Age (y)
65 70 75 80
8.7 10.0 10.8 11.9
10.7 11.9 16.8 —
12.6 17.9 — —
16.8 — — —
21.8 — — —
ave a probability of 20% of requiring reoperation for SVD after 11.9 years, with the
gery c November 2014
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SVD. In deciding between mechanical and biologic mitral
prostheses, the mortality associated with reoperation should
be balanced against the risk of thromboembolic and hemor-
rhagic events associated with anticoagulants.
The results for SVD from our study revealed an overall
actuarial freedom from SVD of 83.9%  2.7% and
23.7%  6.9% at 10 and 20 years, respectively. The ex-
pected valve durability remained satisfactory in the long
term, with a MST of 16.6 years (95% CI, 14.5-19.1) before
valve deterioration. For the specific 50- to 60-year-old pa-
tient group, the expected valve durability remained>15
years (15.7 years). The freedom from reoperation for
SVD was 86.3%  2.5% and 40.5%  8.0% at 10 and
20 years, respectively, with a MST of 19.0 years.
As recommended by Grunkemeier and colleagues9 and
Rahimtoola10 for the study of nonfatal events, we per-
formed a competing risk ‘‘actual’’ analysis, in addition to
the actuarial analyses. After 20 years, the competing risk
analysis demonstrated that the probability of valve-related
mortality was 18.1%  2.4%, reoperation for SVD was
25.4%  2.9%, and noncardiac mortality was 49.6% 
3.2%. For patients aged 65 years at implantation, the
20-year actuarial risk of reoperation for SVD was 23.2%
 5.2% and the cumulative incidence of reoperation for
SVD was 11.5%  2.5%. For patients >70 years, the
20-year actuarial risk and cumulative incidence of reopera-
tion for SVD was 8.5%  3.6% and 4.6%  1.8%,
respectively.
When comparing the expected valve durability with the
sample life expectancy after MVR for the different age
groups, we demonstrated that the expected valve durability
was greater, at least for 90% of the cohort (patients>55
years old at implantation).
Similar clinical outcomes at intermediate-term follow-up
have been reported by others, using the same bioprosthesis.
At 10 years after MVR, the overall freedom from SVD was
81% in the study by Poirier and colleagues14 and 77% in
the study by Murakami and associates.15 In a previous
study, we reported excellent intermediate-term outcomes
with the Carpentier-Edwards PERIMOUNT pericardial
prosthesis in the mitral position,7 in particular, regarding
the lack of premature valve failure or leaflet tear. The
12-year freedom from SVD was 78% for all patients and
was 100% for patients>60 years old at implantation.
No long-term results were found in published studies for
other pericardial valves, in either the aortic or mitral posi-
tion. The intermediate outcomes with the pericardial Sorin
Pericarbon (Sorin Group, Milan, Italy) reported a 12-year
freedom from SVD of 56.8%  6.6% (86.3%  7.5% in
patients>60 years old and 36.8%  8.2% in younger pa-
tients).16 The clinical performance of theMitroflow pericar-
dial bioprosthesis (Sorin Group) was even less satisfactory,
with an 8-year freedom from SVD of 58%  6%.17The Journal of Thoracic and CarThe durability of the Carpentier-Edwards PERIMOUNT
bioprosthesis also compared favorably with the new-
generation porcine valves.18,19 David and colleagues20 re-
ported a 12-year freedom from SVD of 82%  5% with
the Hancock II mitral porcine bioprosthesis (Medtronic,
Parsippany-Troy Hills, NJ) for patients with a mean age of
65 years. Jamieson and colleagues21 compared the second-
generation Carpentier-Edwards Supra-Annular porcine
valve to the Carpentier-Edwards PERIMOUNT bio-
prosthesis. They found that, at 10 years, the freedom from
SVD was lower for the Carpentier-Edwards Supra-Annular
porcine valve (64.7%  3.3% vs 84.0%  3.7% for the
PERIMOUNT in patients aged 60 years and 75.2% 
3.7% vs 95.2%  2.1% for the PERIMOUNT in patients
aged 61-70 years). The direct relationship between age at im-
plantation and bioprosthetic valve durability was especially
pronounced. Comparing the durability of the Carpentier-
Edwards PERIMOUNT pericardial versus porcine bio-
prosthesis, Grunkemeier and colleagues22 reported a rate of
reoperation for SVD of 16%  3.3% at 15 years for the
porcine versus 5%  3.2% at 8 years for the pericardial
valves (P ¼ .13). Despite the shorter follow-up period for
the pericardial cohort, these investigators concluded that a
pericardial valve protected against reoperation for SVD in
the mitral position (HR, 0.39;P¼ .08).22 Patient age at valve
implantation is amajor determinant of life expectancy, risk of
bleeding with anticoagulation treatment,23 and valve dura-
bility. Similar to other studies,18,24,25 we found a significant
relationship between patient age at implantation and the
risk of reoperation for SVD.
Biologic Versus Mechanical
When considering MVR, the appropriate choice between
a mechanical and bioprosthetic valve will often be unclear.
The patient’s age, need for long-term anticoagulation, and
existence of comorbidities are all important considerations
in choosing the best valve for the individual patient.
Direct comparisons of adverse event rates between me-
chanical and bioprosthetic valves have often been difficult,
because the mean age of mechanical valve recipients has
tended to be significantly younger than that of patients
receiving bioprostheses. Holper and colleagues26 reported
on a cohort of patients aged 65 years who had undergone
isolated valve replacement with a mechanical or bio-
prosthetic valve and reported no difference in thromboem-
bolic rates. However, their reported thromboembolic
event-free survival rate for mechanical valves (86% 
6% at 15 years) was lower than that in our experience
(91.5% 2.4% at 15 years and 83.9% 7.6% at 20 years;
linearized rate, 0.6%/valve-year). More precisely, concern-
ing thromboembolic complications after mitral valve sur-
gery, Russo and colleagues27 found that the ischemic
stroke rate at 5 years after MVR with a bioprosthesis was
slightly greater than that after mitral valve repair but wasdiovascular Surgery c Volume 148, Number 5 2009
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 2.1% vs 6.1% 0.9% and 16.1% 2.7%, respectively;
P<.001).
Cannegieter and colleagues28 studied a cohort of patients
receiving oral anticoagulation for mechanical valves (30%
mitral) and reported a bleeding event rate of 3.1%/patient-
year for women and 2.4%/patient-year for men. This was
relatively consistent across the age groups, except for pa-
tients aged 70 years, for whom the risk of bleeding was
twice as high (5.6%/patient-year). Holper and colleagues26
reported a 15-year actuarial freedom from hemorrhage of
88%  4% with a bioprosthesis and 57%  11% with a
mechanical valve. In the present study, despite the relatively
large number of patients (65%) who received oral anticoa-
gulation, the rate of major bleeding (0.7%/valve-year;
20-year actuarial freedom, 80.2%  10.8%) was lower
than that observed in patients receiving a mechanical pros-
thesis.26,29,30 This could be explained by the different
international normalized ratio targets: 2 to 3 for a
bioprosthesis with atrial fibrillation compared with 3 to
4.5 for mechanical valves.
Study Limitations
The present study had a number of limitations. It was a
retrospective study at a single center. The mean age of the
population (68  10.4 years; range, 22-89) was relatively
high compared with that in other published series (60.7 
11.6 years for Marchand and colleagues,4 63.9 11.5 years
for Neville and colleagues7), which can be explained by the
increasing age of patients referred for mitral surgery. The
group of patients <60 years old at implantation was a
selected group, for which we chose to use a bioprosthesis.
The present study also had a performance bias, because
all patients were not treated by the same surgeon. The
mode of follow-up by questionnaire also introduced a risk
of ascertainment bias. However, very few patients were
lost to follow-up (2.2%), and the maximum follow-up
period was 24.8 years. Cardiologic follow-up data were
ensured by the office cardiologists for most patients,
although the observations were, therefore, performed by
various physicians. However, all events were reported as
occurring before or after 30 days, in strict compliance
with American and European guidelines.
CONCLUSIONS
With a low rate of valve-related events at 20 years and, in
particular, a low rate of SVD, the Carpentier-Edwards
PERIMOUNT pericardial bioprosthesis remains a reliable
choice for a tissue valve in the mitral position, especially
in patients>60 years old.
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FIGURE E1. Competing risk analysis of explantation because of struc-
tural valve deterioration (SVD).
FIGURE E2. Valve durability and life expectation by age deciles. MVR,
Mitral valve replacement; MST, median survival time; AUC, area under
the curve; SVD, structural valve deterioration.
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